Dr Reddy's Laboratories EBITDA Margin 2010-2024 | RDY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Dr Reddy's Laboratories average ebitda margin for 2023 was 29.02%, a 31.97% decline from 2022.
Dr Reddy's Laboratories average ebitda margin for 2022 was 21.99%, a 4.81% increase from 2021.
Dr Reddy's Laboratories average ebitda margin for 2021 was 23.1%, a 10.47% decline from 2020.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Dr Reddy's Laboratories average ebitda margin for 2023 was 29.02%, a 31.97% decline from 2022.
Dr Reddy's Laboratories average ebitda margin for 2022 was 21.99%, a 4.81% increase from 2021.
Dr Reddy's Laboratories average ebitda margin for 2021 was 23.1%, a 10.47% decline from 2020.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$19.4B
BridgeBio Pharma (BBIO)	$5.1B
Bausch Health Cos (BHC)	$3.4B
Amphastar Pharmaceuticals (AMPH)	$2.4B
Supernus Pharmaceuticals (SUPN)	$2B
Taysha Gene Therapies (TSHA)	$307M
Personalis (PSNL)	$241M
Assembly Biosciences (ASMB)	$106M
Sol-Gel Technologies (SLGL)	$16M
Evoke Pharma (EVOK)	$5M
Teligent (TLGT)	$0M